


THE POWER OF PLUS WITH PURAPLY® AM

Native extracellular matrix scaffold + sustained antimicrobial effectiveness within the product to support wound healing and aid in granulation tissue formation¹⁻⁴




NATIVE, CROSS-LINKED ECM

- Provides a scaffold for cellular migration and proliferation⁵
- Resists protease degradation^{3,6,7}
- Inhibits a wide range of MMPs and controls excess proteases^{3,6,7}



BROAD-SPECTRUM PHMB

- Proactively disrupts bioburden^{1,3,8}
- Exhibits no known bacterial resistance to date^{3,8,9}
- Demonstrates high tissue compatibility and low cytotoxicity^{2,8,9}



I PuraPly®AM

PROVEN REAL-WORLD EFFECTIVENESS

THE STUDY

N=307
28 Sites

Prospective, multicenter
cohort study⁴

Large
Difficult-to-Heal
Wounds

12.9 cm² mean wound area⁴

THE RESULTS

86% of wounds demonstrated improvement in wound bed conditions⁴



Increased
granulation
tissue



Reduced
exudate



Readiness for
other advanced
skin substitutes

85% of wounds achieved >75% reduction in volume⁴

ECM=extracellular matrix; PHMB=polyhexamethylene biguanide


Note: PuraPly AM resists microbial colonization within the product and reduces microbes penetrating through it. PuraPly AM will naturally be resorbed into the wound and is not intended to be removed.¹

SCIENTIFIC EVIDENCE

ANTIMICROBIAL EFFECTIVENESS WITHIN PURAPLY AM^{2,*}

>99%

MRSA reduction from post-debridement baseline



^aP<0.05 vs pre- and post-debridement baseline; ^bP<0.05 vs Aquacel Ag and PriMatrix Ag; ^cP<0.05 vs BlastX; ^dP<0.05 vs pre-debridement baseline


Data shown compared MRSA (methicillin-resistant *Staphylococcus aureus*) colonies in each wound, using a porcine deep reticular dermal wound model

¹In a study evaluating the antimicrobial effectiveness within PuraPly AM and PuraPly XT versus a variety of other wound products

PURAPLY AM LOW CYTOTOXICITY^{2,*}

>94%



Fibroblast viability at 48 hours



^aP<0.001 vs Blast X

Data shown measured cell proliferation and cell viability using human dermal fibroblasts in media conditioned with test materials

PURAPLY® AM HELPS YOU MANAGE WOUNDS FROM HEAD-TO-TOE WITH A WIDE VARIETY OF SIZES¹



* Abrasions, lacerations, second-degree burns, skin tears

† Donor sites/grfts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence

References: **1.** PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2023. **2.** Davis SC, et al. *Int Wound J.* 2022;19(1):86-99. **3.** Brantley J, et al. *Wounds Int.* 2016;7(3):1-5. **4.** Bain MA, et al. *J Comp Eff Res.* 2020;9(10):691-703. **5.** Data on file. PDR-0008. Organogenesis Inc. **6.** Carpenter S, et al. *Wounds.* 2016;28(6 suppl):S1-S20. **7.** Data on file. PDR-0005. Organogenesis Inc. **8.** Gilbert P, et al. *J Appl Microbiol.* 2005;99(4):703-715. **9.** Hübner NO, et al. *Skin Pharmacol Physiol.* 2010;23(1 suppl):17-27.